Podcast

On Cancer, Coping and Creativity

Author(s):

Brielle Benyon

Ryan Hamner has battled Hodgkin lymphoma four times since the age of 5, and has had some interesting hobbies since - from gardening to metal detecting. But for Hamner, two things stuck: music and creativity.

Ryan Hamner has battled Hodgkin lymphoma four times since the age of 5, and has had some interesting hobbies since - from gardening to metal detecting. But for Hamner, two things stuck: music and creativity.

In this week's episode, we discuss Hamner's journey with cancer, the tools he used to get through it and his creative successes.

Hamner is also a CURE contributor. To read more, visit http://www.curetoday.com/link/93

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Image of two doctors and text.
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Related Content
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice.
July 2nd 2025

Veteran Credits CAR T-Cell Therapy With Helping Him Reach Remission

Spencer Feldman
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma: © stock.adobe.com.
June 18th 2025

FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma

Spencer Feldman
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of hands.
June 14th 2025

From Patient to Researcher: It’s Not All About the Cure

Jessica López
I’m working to make cancer treatments less painful by developing donor-derived CAR therapies, so others don’t have to suffer the way I did.
The ADC zilovertamab vedotin plus Rituxan and chemo showed an ORR of 56.3% in relapsed/refractory DLBCL: © stock.adobe.com.
June 9th 2025

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.